Immunome (IMNM) Price & Analysis

Compare

349 Followers

IMNM Stock Chart & Stats

$18.13

-$0.28(-2.60%)

At close: Jan 08 4:00 PM EST

$18.13

-$0.28(-2.60%)

Day’s Range― - ―

52-Week Range$5.15 - $18.79

Previous CloseN/A

Volume79.27K

Average Volume (3M)1.38M

Market Cap

$1.57B

Enterprise Value$761.36M

Total Cash (Recent Filing)$272.64M

Total Debt (Recent Filing)$4.01M

Price to Earnings (P/E)―

Beta1.85

Next Earnings

Mar 19, 2026

EPS Estimate

-0.57

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.65

Shares Outstanding91,710,270

10 Day Avg. Volume1,613,490

30 Day Avg. Volume1,383,084

Financial Highlights & Ratios

PEG Ratio0.30

Price to Book (P/B)3.44

Price to Sales (P/S)68.88

P/FCF Ratio-5.28

Enterprise Value/Market Cap0.48

Enterprise Value/Revenue78.66

Enterprise Value/Gross Profit-18.92

Enterprise Value/Ebitda-3.78

Forecast

1Y Price Target

$23.57

Price Target Upside30.01% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering10

EPS Forecast (FY)-2.19

Revenue Forecast (FY)$7.86M

Bulls Say, Bears Say

Bulls Say

Pipeline AdvancementsAnalyst recommends buying Immunome, Inc. stock due to strong pipeline advancements in cancer immunotherapy.

Product PotentialVaregacestat, a gamma-secretase inhibitor, shows best-in-class potential with a 75% overall response rate and 45% tumor reduction in Ph2 data.

Strategic PartnershipsThe company's recent strategic partnerships are seen as a positive step towards expanding its research and development capabilities.

Bears Say

Financial ConstraintsThe company has approximately 1.5 years of cash left, which could limit flexibility.

Market RiskMarket volatility is noted as a risk factor that could impact Immunome, Inc.'s stock performance.

Regulatory ChallengesConcerns are raised about the potential regulatory hurdles Immunome, Inc. may face with upcoming product approvals.

Immunome News

Immunome price target raised to $33 from $25 at Stephens

Stephens raised the firm’s price target on Immunome (IMNM) to $33 from $25 and keeps an Overweight rating...

2d ago

IMNM

Immunome reports Q3 EPS (65c), consensus (54c)

As of September 30, 2025, cash and cash equivalents totaled $272.6 million, including net proceeds of $44.9 million...

13d ago

IMNM

Immunome presents preclinical data on ADC payload HC74

Immunome (IMNM) presented preclinical data showing its proprietary antibody-drug conjugate payload HC74 overcomes multiple mechanisms of ADC resistance,...

27d ago

IMNM

Immunome’s Strategic Clinical Advancements and Financial Alignment Justify Buy Rating

TD Cowen analyst Tyler Van Buren has maintained their bullish stance on IMNM stock, giving a Buy rating...

8d ago

IMNM

Immunome, Inc. Reports Q3 2025 Financial Results

Immunome, Inc. ( ($IMNM) ) has released its Q3 earnings. Here is a breakdown of the information Immunome,...

9d ago

IMNM

Immunome’s Strategic Advances and Promising Pipeline Justify Buy Rating

Analyst Charles Zhu from LifeSci Capital maintained a Buy rating on Immunome and keeping the price target at...

13d ago

IMNM

Immunome’s Phase 1 Cancer Study: A Potential Game-Changer?

Immunome, Inc. (($IMNM)) announced an update on their ongoing clinical study. Immunome, Inc. is conducting a Phase 1...

23d ago

IMNM

Immunome’s Promising Pipeline and Management Confidence Drive Buy Rating

Analyst Charles Zhu of LifeSci Capital maintained a Buy rating on Immunome, retaining the price target of $20.00....

1M ago

IMNM

Immunome’s Promising Oncology Pipeline and Strong Market Potential Justify Buy Rating

Salveen Richter, an analyst from Goldman Sachs, has initiated a new Buy rating on Immunome (IMNM). Salveen Richter...

2M ago

IMNM

Immunome initiated with a Buy at Goldman Sachs

Goldman Sachs initiated coverage of Immunome (IMNM) with a Buy rating and $26 price target The firm says...

2M ago

IMNM

Immunome announces novel antibody collaboration with Infinimmune

Infinimmune announced a research collaboration agreement with Immunome (IMNM) for the discovery and optimization of novel antibodies. Under...

2M ago

IMNM

Immunome initiated with a Buy at Craig-Hallum ahead of near-term catalysts

As previously reported, Craig-Hallum initiated coverage of Immunome (IMNM) with a Buy rating and $26 price target Heading...

3M ago

IMNM

Immunome initiated with a Buy at Craig-Hallum

Craig-Hallum initiated coverage of Immunome (IMNM) with a Buy rating and $26 price target Published first on TheFly...

3M ago

IMNM

Immunome’s Varegacestat: Promising Phase 3 Prospects and Competitive Edge in Desmoid Tumor Treatment

LifeSci Capital analyst Charles Zhu maintained a Buy rating on Immunome today and set a price target of...

3M ago

IMNM

IMNM FAQ

What was Immunome’s price range in the past 12 months?

Immunome lowest stock price was $5.15 and its highest was $18.79 in the past 12 months.

What is Immunome’s market cap?

Immunome’s market cap is $1.57B.

When is Immunome’s upcoming earnings report date?

Immunome’s upcoming earnings report date is Mar 19, 2026 which is in 120 days.

How were Immunome’s earnings last quarter?

Immunome released its earnings results on Nov 06, 2025. The company reported -$0.65 earnings per share for the quarter, missing the consensus estimate of -$0.566 by -$0.084.

Is Immunome overvalued?

According to Wall Street analysts Immunome’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Immunome pay dividends?

Immunome does not currently pay dividends.

What is Immunome’s EPS estimate?

Immunome’s EPS estimate is -0.57.

How many shares outstanding does Immunome have?

Immunome has 91,710,270 shares outstanding.

What happened to Immunome’s price movement after its last earnings report?

Immunome reported an EPS of -$0.65 in its last earnings report, missing expectations of -$0.566. Following the earnings report the stock price went down -1.677%.

Which hedge fund is a major shareholder of Immunome?

Currently, no hedge funds are holding shares in IMNM

Immunome Stock Smart Score

Outperform

Fundamentals

Return on Equity

-93.04%

Trailing 12-Months

Asset Growth

16.54%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Immunome

Immunome, Inc. (IMNM) is a biotechnology company focused on developing innovative antibody-based therapies for cancer and other serious diseases. Utilizing its proprietary discovery platform, the company identifies and develops therapeutic candidates derived from the immune response of patients. Immunome aims to address unmet medical needs by creating targeted treatments that harness the body's own immune system to combat disease.

Immunome (IMNM) Earnings & Revenues

Historic Earnings Reports

IMNM Stock 12 Month Forecast

Average Price Target

$23.57

▲(30.01% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","34":"$34","12.25":"$12.25","19.5":"$19.5","26.75":"$26.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$33.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23.57,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$23.57</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$18.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,12.25,19.5,26.75,34],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.07,17.372307692307693,18.674615384615386,19.97692307692308,21.27923076923077,22.581538461538464,23.883846153846154,25.186153846153847,26.48846153846154,27.790769230769232,29.093076923076925,30.395384615384614,31.697692307692307,{"y":33,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.07,16.646923076923077,17.223846153846154,17.80076923076923,18.377692307692307,18.954615384615384,19.53153846153846,20.10846153846154,20.685384615384613,21.262307692307694,21.839230769230767,22.416153846153847,22.993076923076924,{"y":23.57,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.07,16.21846153846154,16.366923076923076,16.515384615384615,16.663846153846155,16.81230769230769,16.96076923076923,17.10923076923077,17.25769230769231,17.406153846153845,17.554615384615385,17.703076923076924,17.85153846153846,{"y":18,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.52,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.59,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.08,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.62,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.4,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.26,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.86,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.06,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.46,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.59,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.28,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.34,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.07,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >